Stockreport

MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

MorphoSys AG - American Depositary Shares  (MOR) 
PDF Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual MeetingBOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June [Read more]